Biopharmx Corp (NYSE:BPMX) Sees Significant Decline in Short Interest
Biopharmx Corp (NYSE:BPMX) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 5,319,631 shares, a drop of 1.7% from the June 15th total of 5,411,971 shares. Currently, 10.2% of the shares of the company are sold short. Based on an average trading volume of 776,056 shares, the short-interest ratio is currently 6.9 days.
Biopharmx Corp (NYSE:BPMX) opened at 0.459 on Friday. The firm has a 50-day moving average of $0.51 and a 200-day moving average of $0.51. Biopharmx Corp has a one year low of $0.19 and a one year high of $1.22. The company’s market cap is $34.03 million.
Separately, ValuEngine raised shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 24th.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.